Washington University School of Medicine

Digital Commons@Becker
ICTS Faculty Publications

Institute of Clinical and Translational Sciences

2008

Attributable outcomes of endemic Clostridium difficile-associated
disease in nonsurgical patients
Erik R. Dubberke
Washington University School of Medicine in St. Louis

Anne M. Butler
Washington University School of Medicine in St. Louis

Kimberly Ann Reske
Washington University School of Medicine in St. Louis

Denis Agniel
Washington University School of Medicine in St. Louis

Margaret A. Olsen
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/icts_facpubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Dubberke, Erik R.; Butler, Anne M.; Reske, Kimberly Ann; Agniel, Denis; Olsen, Margaret A.; D'Angelo, Gina;
McDonald, Clifford; and Fraser, Victoria J., "Attributable outcomes of endemic Clostridium difficileassociated disease in nonsurgical patients". Emerging Infectious Diseases, 1031-1038. 2008. Paper 12.
https://digitalcommons.wustl.edu/icts_facpubs/12

This Article is brought to you for free and open access by the Institute of Clinical and Translational Sciences at
Digital Commons@Becker. It has been accepted for inclusion in ICTS Faculty Publications by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Erik R. Dubberke, Anne M. Butler, Kimberly Ann Reske, Denis Agniel, Margaret A. Olsen, Gina D'Angelo,
Clifford McDonald, and Victoria J. Fraser

This article is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/icts_facpubs/12

Attributable Outcomes of Endemic
Clostridium difficile–associated
Disease in Nonsurgical Patients
Erik R. Dubberke,* Anne M. Butler,* Kimberly A. Reske,* Denis Agniel,* Margaret A. Olsen,*
Gina D’Angelo,* L. Clifford McDonald,† and Victoria J. Fraser*

Data are limited on the attributable outcomes of Clostridium difficile–associated disease (CDAD), particularly in
CDAD-endemic settings. We conducted a retrospective cohort study of nonsurgical inpatients admitted for >48 hours
in 2003 (N = 18,050). The adjusted hazard ratios for readmission (hazard ratio 2.19, 95% confidence interval [CI]
1.87–2.55) and deaths within 180 days (hazard ratio 1.23,
95% CI 1.03–1.46) were significantly different among CDAD
case-patients and noncase patients. In a propensity score
matched-pairs analysis that used a nested subset of the
cohort (N = 706), attributable length of stay attributable to
CDAD was 2.8 days, attributable readmission at 180 days
was 19.3%, and attributable death at 180 days was 5.7%.
CDAD patients were significantly more likely than controls to
be discharged to a long-term-care facility or outside hospital.
Even in a nonoutbreak setting, CDAD had a statistically significant negative impact on patient illness and death, and the
impact of CDAD persisted beyond hospital discharge.

lostridium difficile–associated disease (CDAD) is an
increasingly common cause of hospital-associated diarrhea (1,2). The emerging NAP1 strain of C. difficile has
been associated with numerous outbreaks and appears to
be more virulent than other endemic and epidemic C. difficile strains (3–9). Despite the increasing importance of
this pathogen, few data exist on outcomes attributable to
CDAD (10–14). The attributable mortality for CDAD has
recently been estimated at 6.9% and 16.7% (9,12). However, these studies were performed during CDAD outbreaks caused by the NAP1 strain. Published estimates of
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CDAD-attributable deaths in disease-endemic settings are
much lower (1.2%–1.5%) (10,13). Kyne et al. did not find
endemic CDAD to be an independent predictor of death
within 1 year of CDAD, but that study was relatively small
(47 CDAD cases) (11). Thus, additional data with larger
sample sizes are needed to determine outcomes associated
with CDAD in nonoutbreak settings. With a large cohort
of CDAD patients at a tertiary-care center, we evaluated
CDAD outcomes including length of stay, hospital discharge status, time-to-readmission, and deaths in a CDADendemic setting.
Methods
This study was conducted at Barnes-Jewish Hospital (BJH), a 1,250-bed, tertiary-care academic hospital in
St. Louis, Missouri. Eligibility was limited to nonsurgical
patients admitted for >48 hours from January 1 through
December 31, 2003. Nonsurgical patients were defined as
those without operating room costs. Surgical patients were
excluded because of their heterogeneity. Specifically, risk
factors for length of stay, readmission to the hospital, and
death were different in this population compared with other
hospitalized patients. Data were primarily collected from
the hospital’s Medical Informatics database. The database
was queried to collect patient demographics; admission and
discharge dates; International Classification of Diseases,
9th edition, Clinical Modification (ICD-9-CM), diagnosis and procedure codes (online Appendix, available from
www.cdc.gov/EID/content/14/7/1031-app.htm); inpatient
medication orders; vital signs; and laboratory results, including C. difficile toxin assay results. The Medical Informatics database was also queried to ascertain date of death.
Patients without a death date in the database were screened
for death by reviewing the Social Security Death Index.
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For each patient, a modified APACHE II Acute Physiology Score (APS) was calculated to adjust for severity
of illness (15). The APS was based on laboratory results
and vital signs collected within 24 hours of admission. The
score was modified because data for respiratory rates and
Glasgow coma scores were unavailable electronically. In
addition, the Charlson-Deyo method was used to classify
co-existing conditions (16,17). Albumin levels within 24
hours of admission were collected and categorized into
normal (>3.5 g/dL), low (2.5–3.5 g/dL), and very low (<2.5
g/dL). Multiple imputation methods were used to impute
albumin levels for patients without recorded values (18).
For CDAD case-patients, only medication and intensivecare unit exposures before the patient’s first positive stool
toxin assay were included in analyses.
Case Definition

CDAD case-patients were defined as inpatients with
positive C. difficile stool toxin assays (TechLab, Blacksburg, VA, USA). The microbiology laboratory only performs toxin tests on unformed stool, so all patients with
a positive result for toxin were considered case-patients.
Both community-onset and hospital-onset CDAD casepatients were included in the analyses.
Analyses were performed on the full cohort and a nested case–control population. The first component was a retrospective cohort. For CDAD patients, the admission date
when the patient’s CDAD was first identified was used as
the index admission. For noncases with >1 admission during the study period, 1 admission was randomly selected as
the index admission. The nested case–control population
consisted of propensity score matched cases and controls
from patients identified in the cohort.
Cohort
Data Analysis

Survival was defined as the number of days from the
index hospital admission until death. Survival was censored at 180 days. Time to readmission was calculated as
the number of days between the index hospitalization discharge date and the date of the subsequent admission to
BJH, if applicable. Days until readmission were censored
at death or 180 days, whichever occurred first.
Fisher exact, χ2, and Mann-Whitney U tests were
used to compare characteristics of patients with and without CDAD. Time-to-event methods were used to estimate
the effect of CDAD on 180-day survival and time-to-readmission. Patients who died during the index hospitalization were excluded from the time-to-readmission analysis.
Kaplan-Meier analysis was used to evaluate the unadjusted
relationships between CDAD and time-to-event outcomes.
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Cox proportional hazards regression was used to estimate
unadjusted and adjusted hazard ratios and 95% confidence
intervals (CIs). All variables with biologic plausibility or
p<0.15 in the univariate analysis were considered in the
multivariable Cox regression analysis by using backward
stepwise selection. Variables were sequentially removed
from the final model, starting with the variable most weakly associated with the outcome. The significance of individual covariates was determined by using a Wald statistic of
p<0.05. The proportional hazards assumption was verified
by assessing the parallel nature of curves in log-log plots.
Propensity Score Matched-Pairs Analysis

The second component of this study was a propensity
score matched-pairs analysis of outcomes attributable to
CDAD. This study design complemented the cohort by
enabling analyses that could not be conducted in the entire cohort, specifically hospital discharge status, attributable length of stay, attributable time-to-readmission, and
attributable death. Hospital discharge status could not be
analyzed for the entire cohort because manual review of
medical records was required to determine the discharge
location of each patient. The large size of the cohort prohibited this analysis. In addition, survival and time-to-readmission estimates generated in the cohort analysis were
validated in the matched-pairs analysis.
Cases and a subset of controls were selected from the
primary cohort for the matched-pairs analysis. CDAD casepatients were matched to controls based on their propensity
for CDAD to develop. Patient-specific probabilities of developing CDAD were predicted by a full logistic regression model adjusted for all variables suspected to impact
the risk of developing CDAD (online Appendix). Variables
with p<0.05 in univariate analysis or biologic plausibility
were included in the full logistic regression model. CDAD
case-patients and controls were matched by a 1:1 ratio that
used the nearest-neighbor method within calipers of 0.015
standard deviations (19). CDAD cases without an available
nearest-neighbor control were excluded from the analysis.
Chi-square, Fisher exact, and Mann Whitney U tests were
used, as appropriate, to compare characteristics of CDAD
case-patients and controls.
Medical records were reviewed for all CDAD casepatients and controls to determine hospital discharge location for each patient. Patients were categorized as being
discharged to home, to a long-term-care facility, or to an
outside hospital or dying in the hospital. Long-term-care
facility was defined as a long-term-care facility, long-term
acute-care facility/chronic ventilation facility, inpatient
rehabilitation facility, skilled nursing facility, or nursing
home. Outside hospital was defined as a non-BJH hospital
or acute-care facility.
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Data Analysis

Median length of stay was determined for CDAD casepatients and controls. The difference in median pairwise
length of stay was compared with the Wilcoxon signedrank test. Attributable length of stay was calculated as the
median pairwise difference between CDAD case-patients
and controls. Frequencies, adjusted odds ratios, and 95%
CIs were calculated to determine if discharge location was
associated with CDAD. CDAD-attributable 180-day readmission was calculated as the difference in readmission
between CDAD case-patients and controls. Attributable
deaths from 0–180 days, 0–60 days, and 61–180 days after
admission were also calculated by using this method.
The primary survival endpoints of interest were death
and readmission, which were both censored at 180 days
or at death. Kaplan-Meier analyses, conducted by using
log-rank tests, were used to determine relationships between the survival endpoints and CDAD. Cox proportional hazards regression stratified by matched-pairs was
used to obtain hazard ratios and 95% CIs. Violation of
the proportional hazards assumption was verified by the
crossing nature of curves in the log-log plots. Therefore,
we used an extended Cox regression model stratified by
matched-pairs for the periods <60 days and >60 days. The

breakpoint of 60 days was chosen because the graph of
survival curves for CDAD case-patients and controls diverged at ≈60 days. Violation of the proportional hazards
assumption was confirmed by the significance of the coefficient for the product term between CDAD and <60 days
and >60 days (20).
All tests were 2-tailed, and p<0.05 was considered
significant. Statistical analyses were performed with SPSS
for Windows version 14.0 (SPSS, Inc., Chicago, IL, USA)
and SAS version 9.1 (SAS Institute, Cary, NC, USA). The
Washington University Human Studies Committee approved this project.
Results
Among 18,050 nonsurgical inpatients admitted during the 1-year study period, 390 had CDAD and 17,660
did not. Selected patient characteristics of the cohort are
summarized in Table 1. CDAD patients were significantly
older (median 66.0 vs. 52.7 years, p<0.001) more likely to
be men, and more likely to be Caucasian than were noncase-patients. CDAD case-patients had a higher severity
of illness on admission than noncases, as indicated by the
modified APS. CDAD patients were more likely to have a
diagnosis of congestive heart failure, chronic obstructive

Table 1. Baseline characteristics of study cohort, Clostridium difficile–associated disease (N = 18,050)*
CDAD case-patients (n = 390),
Non–case-patients (n = 17,663),
no. (%)
no. (%)
Characteristic
Age, y
<45
58 (15)
6,847 (39)
45–65
132 (34)
5,187 (29)
>65
200 (51)
5,626 (32)
Male sex
194 (50)
6,704 (38)
White race
257 (66)
9,860 (56)
Modified APS
<2
77 (20)
6,687 (38)
3–4
76 (20)
4,573 (26)
5–6
82 (21)
2,970 (17)
155 (40)
3,430 (19)
 !7
Liver disease
Mild
5 (1)
204 (1)
Moderate to severe
6 (2)
209 (1)
Diabetes without chronic complications
70 (18)
2,718 (15)
Diabetes with chronic complications
15 (4)
416 (2)
Myocardial infarction
26 (7)
1466 (8)
Congestive heart failure
97 (25)
2,562 (15)
Cerebral vascular disease
16 (4)
882 (5)
Chronic obstructive pulmonary disease
90 (23)
2,564 (15)
Rheumatologic/collagen vascular disease
11 (3)
361 (2)
Peptic ulcer disease
5 (1)
279 (2)
Cancer, excluding leukemia or lymphoma
45 (12)
1,283 (7)
Leukemia or lymphoma
69 (18)
567 (3)
Metastatic solid tumor
33 (9)
936 (5)
HIV/AIDS
5 (1)
209 (1)
Paraplegia or hemiplegia
8 (2)
223 (1)

p value†
<0.001
0.06
<0.001
<0.001
<0.001
<0.001
0.004
0.028
<0.001
0.77
0.47
0.17
0.06
0.25
<0.001
0.42
<0.001
0.29
0.64
0.001
<0.001
0.01
0.81
0.17

*CDAD, Clostridium difficile–associated disease; APS, Acute Physiology Score.
† Fisher exact test, Ȥ2 test.
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pulmonary disease, cancer, leukemia or lymphoma, and
metastatic solid tumors.
Of 17,492 patients alive at the index hospitalization
discharge, 4,207 (24%) were readmitted to BJH within
180 days. Fifty-two percent of CDAD patients were readmitted within 180 days versus 23% of noncases (log-rank
p<0.001). Univariate and multivariable Cox regression results for time to readmission are presented in Table 2. The
adjusted hazard ratio (HR) for readmission within 180 days
was significantly higher for CDAD case-patients than noncases (HR 2.19, 95% CI 1.87–2.55) (Table 2).
By 180 days after hospital admission, 149 (38%) of
390 CDAD case-patients and 2,150 (12%) 17,660 noncasepatients had died. In the Kaplan-Meier analysis, the mortality rate was significantly higher for CDAD case-patients
than noncases (log rank p<0.001) (Figure 1). Unadjusted
and adjusted Cox regression results for death within 180
days of admission (“180-day mortality”) are presented in
Table 3. The adjusted hazard ratio for 180-day mortality
was significantly higher for CDAD case-patients than noncase patients (HR 1.23, 95% CI 1.03–1.46) (Table 3).
The propensity score matched-pairs analysis included
353 CDAD cases and 353 controls (N = 706). There were

Figure 1. Kaplan-Meier survival estimates for cohort (N = 18,050).
CDAD, Clostridium difficile–associated disease.

no significant differences between the matched cases and
controls after correcting for multiple testing with the Bonferroni procedure. Thirty-seven CDAD case-patients were

Table 2. Cox proportional hazards estimate of readmission at 180 d in Clostridium difficile–associated disease (CDAD) study cohort
(N = 17,492; 4,207 readmissions, 13,285 censored)*†
Variable
Univariate hazard ratio‡ (95% CI)
Multivariable hazard ratio ‡ (95% CI)
CDAD
3.09 (2.95–3.23)
2.19 (1.87–2.55)
Male sex
1.42 (1.40–1.45)
1.11 (1.05–1.19)
White race
1.26 (1.23–1.28)
1.06 (1.00–1.13)
Modified APS
<2
Reference
Reference
3–4
1.15 (1.12–1.18)
1.10 (1.02–1.20)
5–6
1.39 (1.35–1.43)
1.24 (1.13–1.35)
1.84 (1.80–1.89)
1.50 (1.37–1.64)
 !7
Albumin, g/dL§
>3.5
Reference
Reference
2.5–3.5
1.05 (1.03–1.08)
0.99 (0.92–1.08)
<2.5
1.03 (0.99–1.07)
0.95 (0.80–1.14)
Liver disease
None
Reference
Reference
Mild
1.80 (1.67–1.94)
1.44 (1.12–1.83)
Moderate to severe
1.79 (1.65–1.94)
1.48 (1.13–1.93)
Diabetes with chronic complications
1.89 (1.80–1.99)
1.53 (1.30–1.80)
Diabetes without chronic complications
1.29 (1.26–1.32)
1.10 (1.02–1.19)
Congestive heart failure
1.60 (1.56–1.64)
1.34 (1.23–1.45)
Cerebrovascular disease
0.77 (0.74–0.81)
0.74 (0.63–0.87)
Cancer, excluding leukemia or lymphoma
2.75 (2.67–2.83)
1.90 (1.70–2.13)
Leukemia or lymphoma
2.31 (2.18–2.45)
1.84 (1.52–2.23)
Metastatic solid tumor
2.81 (2.71–2.91)
1.66 (1.46–1.90)
HIV/AIDS
1.74 (1.62–1.87)
1.74 (1.38–2.19)
ICU admission
1.06 (1.03–1.09)
0.84 (0.76–0.93)
*CI, confidence interval; APS, Acute Physiology Score; ICU, intensive care unit.
†The analysis excluded 558 patients who died during the index hospital admission. Nonsignificant variables considered in the model included mechanical
ventilation, paraplegia/hemiplegia, chronic obstructive pulmonary disease, myocardial infarction, rheumatologic/collagen vascular disease, and peptic
ulcer disease.
‡Hazard ratios also adjusted for categorical age (<20, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84,
85–89, 90–94, >95 y).
§7,610 (42%) patients were missing albumin values. Values were imputed by using multiple imputation methods.
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Table 3. Cox proportional hazards estimate of deaths from Clostridium difficile–associated disease (CDAD) at 180 d in study cohort
(N = 18,050; 2,299 deaths, 15,751 censored)*†
Variable
Univariate hazard ratio‡ (95% CI)
Multivariable hazard ratio‡ (95% CI)
CDAD
3.55 (3.37–3.75)
1.23 (1.03–1.46)
Male sex
1.73 (1.68–1.77)
1.17 (1.08–1.27)
White race
1.65 (1.61–1.70)
1.22 (1.11–1.33)
Modified APS
<2
Reference
Reference
3–4
1.41 (1.36–1.47)
1.09 (0.96–1.24)
5–6
2.09 (2.00–2.17)
1.30 (1.14–1.49)
4.11 (3.97–4.25)
1.65 (1.46–1.87)
>7
Albumin, g/dL§
>3.5
Reference
Reference
2.5–3.5
2.12 (1.90–2.36)
1.62 (1.45–1.82)
<2.5
4.77 (3.91–5.81)
2.93 (2.52–3.42)
Liver disease
None
Reference
Reference
Mild
3.08 (2.86–3.33)
2.37 (1.85–3.04)
Moderate to severe
5.50 (5.17–5.85)
3.76 (3.05–4.64)
Diabetes with chronic complications
1.47 (1.37–1.58)
1.49 (1.18–1.88)
Congestive heart failure
1.85 (1.80–1.91)
1.28 (1.15–1.42)
Cerebrovascular disease
1.68 (1.60–1.76)
1.62 (1.37–1.92)
Cancer, excluding leukemia or lymphoma
6.42 (6.24–6.61)
2.44 (2.15–2.76)
Leukemia or lymphoma
3.17 (2.99–3.38)
4.92 (3.98–6.08)
Metastatic solid tumor
8.82 (8.57–9.09)
4.41 (3.87–5.03)
HIV/AIDS
1.77 (1.62–1.95)
2.88 (2.12–3.91)
Paraplegia/ hemiplegia
1.75 (1.60–1.92)
1.53 (1.12–2.07)
Mechanical ventilation
6.39 (6.18–6.62)
3.17 (2.71–3.71)
ICU admission
3.08 (2.99–3.17)
1.31 (1.14–1.50)
*CI, confidence interval; APS, Acute Physiology Score; ICU, intensive care unit.
†Nonsignificant variables considered in the model included diabetes without chronic complications, chronic obstructive pulmonary disease, myocardial
infarction, rheumatologic/collagen vascular disease and peptic ulcer disease. Of 2,299 people who died within 180 d of admission, 1,565 (68%) deaths
were identified by means of the hospital Medical Informatics database and 734 (32%) were identified with the Social Security Death Index.
‡Hazard ratios also adjusted for categorical age (<20, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84,
85–89, 90–94, t95 y).
§7,525 (43%) patients were missing albumin values. Values were imputed by using multiple imputation methods.

dropped because a nearest-neighbor control was not available. Unmatched CDAD patients had significantly higher
modified APS (median = 7.0 vs. 5.0, p<0.001), longer median length of stay (13.6 days vs. 9.6 days, p = 0.01), and
higher percentage of deaths at 180 days (59% vs. 36%, p =
0.01) than matched case-patients.
In the matched-pairs analysis, median length of stay
was 9.6 days for CDAD patients compared with 5.8 days
for controls, and the increased attributable length of stay
for CDAD patients was 2.8 days (Wilcoxon signed-rank
p<0.001). Among the 706 patients in the matched-pairs analysis, 445 (63%) were discharged to home and 188 (27%)
were discharged to a long-term-care facility. Only 7 (1%)
patients were discharged to an outside hospital; therefore,
these patients were combined with patients discharged to a
long-term-care facility in the analysis. CDAD patients were
significantly more likely than controls to be discharged to
a long-term-care facility or outside hospital (32% vs. 23%,
odds ratio 1.62, 95% CI 1.15–2.28, McNemar p = 0.01).
Among 290 matched-pairs with both patient and control alive at index hospitalization discharge, 148 CDAD

patients were readmitted to BJH within 180 days compared
with 92 controls, for an attributable readmission of 19.3%
(11.4%–27.2%). In the Kaplan-Meier and Cox model analyses, CDAD patients were significantly more likely than
controls to be readmitted to the hospital within 180 days
(Figure 2, Table 4).
By 180 days after hospital admission, 127 CDAD
patients died compared with 107 controls, for an attributable mortality of 5.7% (95% CI –1.3%–12.6%). Although
CDAD case-patients were no more likely than controls to
die within 60 days of hospital admission, a divergence in
survival between CDAD case-patients and controls began
60 days after hospital admission (Figure 3, Table 4). The
HR for death from 61–180 days was significantly higher
for CDAD patients than controls (HR 2.00, 95% CI 1.47–
2.72) (Table 4). Among 223 matched-pairs with both casepatients and controls alive after day 60, 19.7% of CDAD
patients and 12.6% of controls died within 180 days for an
attributable mortality between 61–180 days of 7.2% (95%
CI 0.4%–14.0%).
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Figure 2. Kaplan-Meier estimates of time until hospital readmission
for matched pairs (n = 580). CDAD, Clostridium difficile–associated
disease.

Discussion
The results of this study indicate that CDAD is a major contributor to death even in nonoutbreak settings. In this
CDAD-endemic setting, the disease was associated with a
23% higher hazard of death within 180 days after hospital
admission in the multivariable cohort analysis and a 7.2%
attributable mortality 61–180 days after hospital admission
in the matched-pairs analysis. Historically, endemic CDAD
has been reported to be associated with minimal increased
risk in mortality although NAP1 strain CDAD outbreaks
have been associated with much higher attributable mortality (10,11,13). Two studies of CDAD in endemic settings
reported 1.2%–1.5% inhospital mortality rates from CDAD
(10,13). Using a multivariable Cox proportional hazards
model, Kyne et al. found no association between CDAD
and 1-year mortality, although that study was quite small
(47 CDAD patients) (11). In contrast, several studies have
identified increased deaths associated with outbreaks of the
NAP1 strain. Pepin et al. estimated the 1-year attributable
mortality of CDAD during an outbreak with the NAP1 strain
to be 16.7% (9). Hubert et al. reported that CDAD was the
attributable or contributive cause of death in 8.4% of patients
infected with a strain of C. difficile that had the binary toxin

and tcdC deletion (21). Loo et al. found CDAD to be the attributable cause of death within 30 days in 6.9% of CDAD
patients and suspected that CDAD contributed to death in
another 7.5% of CDAD patients (12). The estimate of 6.9%
attributable mortality, however, was determined through
chart review, not through multivariable analyses, and medical chart review may not be an adequate method to determine
attributable mortality because of subjectivity (22).
Although the 5.7% 180-day attributable mortality determined in the propensity score matched-pairs analysis
in our study was not statistically significant, the estimate
is substantially higher than estimates reported from other
CDAD-endemic settings. The attributable mortality we report is more consistent with estimates from outbreaks of the
NAP1 strain and is likely clinically significant. The NAP1
strain was first identified at BJH during 2005, but the strain
may have been present during the study period (23). During
the years 2000–2006 at BJH, there were no apparent increases in hospital-onset CDAD incidence rates or severity
of CDAD (as measured by the number of colectomies per
CDAD case per year and by the percentage of patients with
CDAD who died during hospitalization) (data not shown).
Thus, the high attributable mortality found in this study has
important implications for patients: CDAD remains an important cause of patient death even in a CDAD-endemic
setting.
Our study showed that CDAD had a delayed impact
on death. In the matched-pairs analysis, the divergence in
survival between CDAD cases-patients and controls did
not begin until >60 days after hospital admission. Within
60 days of admission, survival was not significantly different between CDAD patients and controls, when all but 4
(1%) patients had been discharged from the hospital. This
finding is consistent with those of 2 recent nested matched
case–control studies in nonoutbreak settings, in which no
significant excess deaths were reported after 30 days (24)
or at discharge (25). Although CDAD can be acutely lifethreatening, delayed death caused by CDAD may not be
easily recognized as related to the initial CDAD episode.
CDAD may contribute to a decline in patient function and
overall illness over time, ultimately leading to death in
many patients.
The results of the time-to-readmission and discharge
location analyses further emphasize the negative impact of

Table 4. Cox proportional hazards model estimates of readmission and death of matched-pairs analysis, Clostridium difficile–
associated disease (CDAD)*
Variable
CDAD case-patients, no. (%)
Controls, no. (%)
Hazard ratio (95% CI)
Readmitted within 180 d†
148 (51.0)
92 (31.7)
2.17 (1.59–2.95)
Deaths at 180 d‡
127 (36.0)
107 (30.3)
1.22 (0.92–1.61)
Deaths at 0–60 d‡
72 (20.4)
75 (21.2)
0.96 (0.54–1.70)
Deaths at 61–180 d‡
55 (15.6)
32 (9.1)
2.00 (1.47–2.72)
*CI, confidence interval.
†n = 290 matched pairs; 63 matched pairs were excluded because one or both patients in the pair died during the index hospital admission.
‡n = 353 matched pairs.
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Figure 3. Kaplan-Meier survival estimates for matched pairs (n =
706). CDAD, Clostridium difficile–associated disease.

CDAD. CDAD patients were more than twice as likely to
be readmitted to BJH within 180 days compared with controls. This finding is consistent with our prior findings that
CDAD contributes to an increase in hospital costs extending out to at least 180 days (26). CDAD patients were also
significantly more likely to be discharged to a long-termcare facility or outside hospital. Few data are available on
the health of CDAD patients after hospital discharge, and
future studies following CDAD patients as outpatients over
an extended period are needed.
Data on the excess length of hospital stay attributable
to CDAD are limited. Wilcox et al. found that CDAD patients stayed in the hospital, on average, 21.3 days longer
than non-CDAD patients; however, the attributable length
of stay was not calculated (14). O’Brien et al. reported that
the mean increase in hospitalization among CDAD patients
was 2.9 days (27). Kyne et al. calculated the attributable
length of stay at 3.6 days (11), which was comparable to
the attributable length of stay estimate found in our study
(2.8 days).
Our study has several limitations, including the retrospective study design. Use of electronic data from the
hospital’s Medical Informatics database has limitations,
although use of these data made analysis of such a large cohort feasible. Differences seen in observational studies may
be due to unmeasured confounders. We attempted to address this issue by using 2 methods to control for confounding: multivariable regression analyses and propensity score
matched-pairs analyses. As evident from the Kaplan-Meier
mortality analyses, the matched-pairs population is a more
homogeneous population than the cohort. This design allows more precise effect estimation because the association

between CDAD and the propensity score variables among
the study participants is eliminated. A strength of the multivariable regression analyses is the use of all available
data in the cohort. In the propensity score matched-pairs
analyses, 37 CDAD cases were excluded because of lack
of a suitable control. Unmatched case-patients were more
severely ill than matched case-patients, and their exclusion
is a limitation of the propensity-score matched-pairs analyses. In the time-to-readmission analyses, we were unable to
identify readmissions to hospitals other than our institution.
Finally, surgical patients were excluded from these analyses. Because of this exclusion, the most severely ill CDAD
patients requiring colectomies (n = 3) were not represented
in the dataset. The absence of these patients, as well as the
37 unmatched case-patients, may have resulted in estimates
of attributable length of stay and death that are biased low.
Data on attributable outcomes associated with CDAD
are scarce. As previously mentioned, some data on attributable mortality and length of stay exist; however, these findings are limited by lack of adequate controls, small sample
size, or outbreak settings. Our study provided detailed
analysis on the effect of CDAD on time-to-readmission.
Another key strength of this study is the combination of
2 analytical methods: Cox proportional hazards regression in the primary cohort and propensity score matchedpairs analysis. Mortality and time-to-readmission analyses,
which were conducted in both the cohort and matchedpairs populations, had remarkably similar results. The results of this study suggest that endemic CDAD can lead to
significantly poorer patient outcomes, including increased
hospital length of stay, death, risk for admission to a longterm-care facility, and risk for hospital readmission. Even
when the most severe CDAD cases are not considered, the
detrimental effect of CDAD on patient health appears to
extend beyond hospital discharge. Although prospective
validation of these findings is needed, proper allocation of
healthcare resources toward prevention of this infection is
necessary to prevent further illness and death attributable
to CDAD.
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